Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L34 pseudogene 20 is a processed pseudogene in the human genome, annotated as RPL34P20. It is a sequence homologous to the RPL34 gene, which encodes a protein component of the large 60S ribosomal subunit, but RPL34P20 does not produce a functional protein. Like many ribosomal protein genes, multiple related pseudogenes exist as remnants of evolutionary duplication events. There is no evidence for protein-coding capacity, biological function, or relevance as a therapeutic target, disease gene, or biomarker. The presence of RPL34P20 in the genome is of academic interest primarily for studies of genome evolution and gene family expansion but not for clinical, pharmacological, or therapeutic purposes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L34 pseudogene 20 (RPL34P20).